NCT03866382 2026-03-18
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
823 trialsNCT04071236 2026-03-18
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT04314401 2026-03-18
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Recruiting
NCT04895839 2026-03-18
PC-PEP
Nova Scotia Health Authority
Phase NA Recruiting
NCT05435495 2026-03-18
Mechanisms of Resistance to PSMA Radioligand Therapy
University of California, San Francisco
Recruiting
NCT05691465 2026-03-18
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06970847 2026-03-18
AMPLIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT06995898 2026-03-18
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Phase NA Recruiting
NCT07424547 2026-03-18
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
Phase 1 Recruiting
NCT02064673 2026-03-17
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
University of Texas Southwestern Medical Center
Phase 3 Recruiting
NCT05888532 2026-03-17
64Cu-GRIP B in Patients With Advanced Malignancies
University of California, San Francisco
Phase 1/2 Recruiting
NCT06879041 2026-03-17
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
Phase 1 Recruiting
NCT06926075 2026-03-17
ADVICE
Filamon LTD
Phase 1/2 Recruiting
NCT07111507 2026-03-17
A Study of Tarlatamab for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07332000 2026-03-17
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
NCT07398690 2026-03-17
INSIGHT-PCa
Asan Medical Center
Phase NA Recruiting
NCT05751941 2026-03-16
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06056830 2026-03-16
CLARIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT06096870 2026-03-16
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06651632 2026-03-16
WATER IV PCa
PROCEPT BioRobotics
Phase NA Recruiting
NCT06780670 2026-03-16
PSMAcTION
Novartis
Phase 2/3 Recruiting
NCT07103018 2026-03-16
STRIKE-001
K36 Therapeutics, Inc.
Phase 1 Recruiting
NCT07245745 2026-03-16
Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase NA Recruiting
NCT07422597 2026-03-16
PRORAND
Norwegian University of Science and Technology
Phase NA Recruiting
NCT07474142 2026-03-16
PSMA-VISION
Xijing Hospital
Recruiting
NCT04788277 2026-03-13
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
Thomas Jefferson University
Recruiting
NCT04857502 2026-03-13
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05616650 2026-03-13
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting
NCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06925737 2026-03-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07025369 2026-03-13
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Mayo Clinic
Phase 2 Recruiting
NCT07082920 2026-03-13
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07319871 2026-03-13
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07335796 2026-03-13
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04585750 2026-03-12
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
Phase 1/2 Recruiting
NCT05361798 2026-03-12
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05417594 2026-03-12
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT06511141 2026-03-12
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Axonics, Inc.
Phase NA Recruiting
NCT06523634 2026-03-12
STEREOBED
Jules Bordet Institute
Phase NA Recruiting
NCT06835218 2026-03-12
PROCARE
UroTrials Company (GmbH)
Recruiting
NCT07460843 2026-03-12
Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis
Peking University First Hospital
Phase NA Recruiting
NCT03424850 2026-03-11
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
Washington University School of Medicine
Phase 1/2 Recruiting
NCT06040125 2026-03-11
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT06437574 2026-03-11
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT06542757 2026-03-11
Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy
NYU Langone Health
Phase NA Recruiting
NCT07090148 2026-03-11
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
Phase 1 Recruiting
NCT06067295 2026-03-10
Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
University of Southern California
Recruiting
NCT06216249 2026-03-10
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07188064 2026-03-10
PRP NG PRO M
Sir Mortimer B. Davis - Jewish General Hospital
Phase NA Recruiting